Companies /Healthcare

Cerus Corp

NASDAQ: CERS Medical Devices
$1.94
▲ $0.04 (+2.11%) today
Markets closed · 4:18am ET

CERS at a Glance

Valuation
Market cap
$383.7M
Profitability
Revenue (TTM)
$226.6M
Profit margin
-3.2%
EPS (TTM)
$-0.04
Price
52-week range
$1 – $3
Street target
$5.12

Headquartered in Concord, CA Fiscal year ends December NASDAQ: CERS cerus.com

About Cerus

Cerus Corporation is a blood products company focused on safeguarding the global blood supply. It develops and supplies pathogen reduction technologies and pathogen-protected blood components to blood centers and hospitals.

Its core INTERCEPT Blood System for platelets and plasma is sold globally. Cerus says it is the only pathogen reduction system with both CE mark and FDA approval for these two blood components.

In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, or IFC). IFC is a therapeutic product used to treat and control bleeding, including massive hemorrhage, associated with fibrinogen deficiency. It is sold both as kits and as finished therapeutic doses.

The company also sells INT200 illuminators. These are commercially launched internationally, including EMEA, and a U.S. PMA submission is under FDA review.

Cerus earns government contract revenue through BARDA-funded development of its red blood cell system. That system is under regulatory review in Europe and in late-stage U.S. clinical development, and recently reported positive topline Phase 3 RedeS results.

Product revenue is concentrated in North America and Europe, Middle East and Africa. The company also holds a noncontrolling-interest joint venture in China, Cerus Zhongbaokang (Shandong) Biomedical. Updated

Latest Activity

CERSCerus
Q3 2026
EPS
$0.00
est -$0.01+$0.01
Revenue
$64M
est $61M+4.8%

Cerus broke even on the bottom line, beating expectations, as INTERCEPT Fibrinogen Complex volumes grew roughly 80%. Positive topline Phase 3 RedeS data for the red blood cell system landed the same day, pushing a much larger market within regulatory reach.

Quarterly EPS — reported vs estimate

CERS Coverage

Frequently Asked Questions

What does Cerus do?

Cerus Corporation is a blood products company focused on safeguarding the global blood supply. It develops and supplies pathogen reduction technologies and pathogen-protected blood components to blood centers and hospitals.

What is the CERS stock price target?

The Wall Street consensus 12-month price target for CERS is $5.12.